Online inquiry

IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2598MR)

This product GTTS-WQ2598MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MPL gene. The antibody can be applied in Chronic immune (idiopathic) thrombocytopenic purpurea (ITP) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005373.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4352
UniProt ID P40238
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2598MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13719MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ11817MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ9377MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ13643MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ14578MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aCD1919
GTTS-WQ9863MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ7606MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ5449MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDA 1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW